On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets. The workshop will be held at the FDA’s White Oak Campus in Silver Spring, Maryland and will also be webcast.
Workshop panelists will discuss the agencies’ efforts to support competition between biosimilars and reference biologics, discouraging false or misleading statements about biosimilars’ safety and efficacy, and deterring anticompetitive behaviors in the biologic marketplace. Last month, the FTC and the FDA signed a joint statement promoting competition in markets for biologics.
For more information about viewing the webcast, and for background information on the event, see the FDA’s meeting announcement. All available tickets for onsite seating are reserved, but registration for the webcast is still available. The webcast will also be archived for later viewing.
The Federal Trade Commission develops policy initiatives on issues that affect competition, consumers, and the U.S. economy. Like the FTC on Facebook, follow us on Twitter, read our blogs, and subscribe to press releases for the latest FTC news and resources.
WASHINGTON – Today, the U.S. Department of the Treasury (Treasury), as Chair of the Committee…
WASHINGTON—Today, the U.S. Department of the Treasury’s Community Development Financial Institutions Fund (CDFI Fund) and…
Washington – The findings from the annual survey of U.S. portfolio holdings of foreign securities…
WASHINGTON – The U.S. Department of the Treasury hosted a roundtable on October 30 with…
WASHINGTON – The United States and the People’s Republic of China held the sixth meeting…
WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…